Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
| ▸ | BRAF | P15056 | 4/20 | 0.33 |
| ▸ | JAK1 | P23458 | 3/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | PLK4 | O00444 | 1/20 | 0.32 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.32 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.32 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10096710 | 0.97 | MEN1 (0.38) | PGRMEN1ALDH1A1LMNAHPGD | |
| SCHEMBL10096478 | 0.94 | PGR (0.38) | PGRMEN1ALDH1A1LMNAHPGD | |
| SCHEMBL10096225 | 0.93 | PGR (0.40) | PGRMEN1ALDH1A1LMNAHPGD | |
| SCHEMBL10096721 | 0.92 | MEN1 (0.38) | PGRMEN1ALDH1A1LMNAHPGD | |
| SCHEMBL10096720 | 0.92 | ALDH1A1 (0.38) | PGRMEN1ALDH1A1LMNAHPGD | |
| SCHEMBL10096422 | 0.91 | LMNA (0.40) | PGRMEN1ALDH1A1LMNAHPGD | |
| SCHEMBL12995995 | 0.90 | PGR (0.38) | PGRMEN1ALDH1A1LMNAHPGD | |
| SCHEMBL12105747 | 0.90 | HRH3 (0.39) | PGRMEN1ALDH1A1LMNAHPGD | |
| SCHEMBL12996072 | 0.90 | ADRB2 (0.38) | PGRMEN1ALDH1A1LMNAHPGD | |
| SCHEMBL12996395 | 0.89 | PGR (0.37) | PGRMEN1ALDH1A1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927576-B2 | HCV inhibitor and therapeutic agent combinations | PTC Therpeutics, Inc. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927576-B2 | HCV inhibitor and therapeutic agent combinations | PTC Therpeutics, Inc. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-7772271-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772271-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20070299068-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299068-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299068-A1 | Methods for treating hepatitis C | HAVCR2, EIF2AK2, MAVS | PGR 1823/4885MEN1 4800/4885ALDH1A1 1497/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | PGR 1823/4885MEN1 4800/4885ALDH1A1 1497/4885 |
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | HAVCR2, SERPINB1, ENPEP | PGR 3813/4885MEN1 4860/4885ALDH1A1 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.